EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology

Yasra Fatima iD, Kirubel Nigusu Jobre iD, Enrique Gomez-Gomez iD, Bartosz Małkiewicz iD, Antonia Vlahou iD, Marika Mokou iD, Harald Mischak iD, Maria Frantzi iD, Vera Jankowski iD

International Journal of Molecular Sciences · 02.08.2025 · 26 (15) · 7475

DOI: 10.3390/ijms26157475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.08.2025. Verfasst von Yasra Fatima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomarker Research, Mosaiques Diagnostics GmbH, 30659 Hannover, Germany. Hauptthemen laut MEDLINE: Precision Medicine, Genomics, Prostatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marie Skłodowska Curie Actions Doctoral Networks Industrial Doctorates Programme project PROMOTE, BMBF (Federal Ministry of Education and Research), Deutsche Forschungsgemeinschaft´ (DFG, German Research Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer accounts for approximately 1.5 million new diagnoses and 400,000 deaths every year worldwide, and demographic projections indicate a near-doubling of both figures by 2040. Despite existing treatments, 10–20% of patients eventually progress to metastatic castration-resistant disease (mCRPC). The median overall survival (OS) after progression to mCPRC drops to 24 months, and efficacy drops severely after each additional line of treatment. Omics platforms have reached advanced levels and enable the acquisition of high-resolution large datasets that can provide insights into the molecular mechanisms underlying PCa pathology. Genomics, especially DDR (DNA damage response) gene alterations, detected via tissue and/or circulating tumor DNA, efficiently guides therapy in advanced prostate cancer. Given recent developments, we have performed a comprehensive literature search to cover recent research and clinical trial reports (over the last five years) that integrate omics along three converging trajectories in therapeutic development: (i) predicting response to approved agents with demonstrated survival benefits, (ii) stratifying patients to receive therapies in clinical trials, (iii) guiding drug development as part of drug repurposing frameworks. Collectively, this review is intended to serve as a comprehensive resource of recent advancements in omics-guided therapies for advanced prostate cancer, a clinical setting with existing clinical needs and poor outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineGenomicsProstatic NeoplasmsHumansMaleProstatic Neoplasms, Castration-ResistantBiomarkers, Tumor

Stichwörter der Autor:innen

biomarker-guided therapycombination therapymulti-omicspersonalized medicineprecision oncologytherapeutic interventionstreatment response prediction

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biomarker Research, Mosaiques Diagnostics GmbH, 30659 Hannover, Germany.
  • Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, 52074 Aachen, Germany.
  • Urology Department, Reina Sofía University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), University of Cordoba (UCO), 14004 Cordoba, Spain.
  • Department of Minimally Invasive and Robotic Urology, Centre of Excellence in Urology, Wroclaw Medical University, 213 Borowska Street, 50-556 Wroclaw, Poland.
  • Systems Biology Center, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece.

ORCID-Profile: Yasra Fatima, Kirubel Nigusu Jobre, Enrique Gomez-Gomez, Bartosz Małkiewicz, Antonia Vlahou, Marika Mokou, Harald Mischak, Maria Frantzi, Vera Jankowski

Förderung

  • Marie Skłodowska Curie Actions Doctoral Networks Industrial Doctorates Programme project PROMOTE
  • BMBF (Federal Ministry of Education and Research)
  • Deutsche Forschungsgemeinschaft´ (DFG, German Research Foundation)
  • CRU 5011
  • Cost-Action CA
  • European Union Horizon Europe Marie Skłodowska Curie Actions Doctoral Networks Industrial Doctorates Programme project PROMOTE
  • ‘Deutsche Forschungsgemeinschaft’ (DFG, German Research Foundation)

Zitieren

APA

Fatima, Y., Jobre, K. N., Gomez-Gomez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025). Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology. International Journal of Molecular Sciences, 26(15), 7475. https://doi.org/10.3390/ijms26157475

Vancouver

Fatima Y, Jobre KN, Gomez-Gomez E, Małkiewicz B, Vlahou A, Mokou M, et al. Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology. International Journal of Molecular Sciences. 2025;26(15):7475. doi:10.3390/ijms26157475

BibTeX
@article{Fatima2025,
  author = {Fatima, Yasra and Jobre, Kirubel Nigusu and Gomez-Gomez, Enrique and Małkiewicz, Bartosz and Vlahou, Antonia and Mokou, Marika and Mischak, Harald and Frantzi, Maria and Jankowski, Vera},
  title = {Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {15},
  pages = {7475},
  doi = {10.3390/ijms26157475}
}
Kostenlos starten →